New Approaches, New Hope
Learn More About OncoSec
IL-12 TAVO
INVESTIGATIONAL INTRATUMORAL
CANCER IMMUNOTHERAPY

Learn About OncoSec

CEO LETTER OncoSec CEO, Daniel J. O’Connor, Letter to Shareholders

PARTNERSHIPS  Collaboration with Dana-Farber Cancer Institute

NEW VISCERAL LESION APPLICATOR  OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)

VIDEO  TAVO Demonstration

PRESENTATION  Corporate Presentation

Clinical trials of today may power the medical advances of tomorrow

Learn more about our current clinical trials:

MerckAdvanced Melanoma

Triple Negative Breast Cancer

Spotlight 

Nature Gene Therapy: Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy

Immuno-Oncology News: TAVO reverses resistance to PD-1 inhibitors in metastatic melanoma, phase 2b trial suggests

Health Professionals Radio: President and CEO Dan O’Connor discusses late-stage studies in melanoma and TNBC.

News & Events

Jul 16, 2019
OncoSec Issues Letter to Shareholders
Jun 27, 2019
OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers
Jun 17, 2019
OncoSec Announces Research Collaboration with Roswell Park Comprehensive Cancer Center Using Cutting-Edge Intravital Microscopy (IVM), TAVO-PLUS and APOLLO™ Electroporation Generator
Jun 13, 2019
OncoSec to Present Immunological Data at World Pharma Week 2019
May 29, 2019
OncoSec Announces Collaboration For TAVO™ In Australia With Emerge Health
May 28, 2019
OncoSec Medical Incorporated Announces Closing of $11.0 Million Public Offering and Terminates ATM and Other Financing Facility

Tavokinogene Telseplasmid “TAVO” IL-12

Designed to take the fight directly to the tumor

We are investigating the potential for our lead product candidate, TAVO, through the intratumoral administration of IL-12, to stimulate systemic immune response and to become an innovative and potentially transformative therapy option for the treatment of cancer.

Learn More

Designed to Arm the Immune System to Fight Cancer

Clinical Pipeline

Pipeline
Our core technology platform continues to advance through clinical trials for various cancers.

Learn More

Technology

Technology
The Intratumoral IL-12 platform is designed to boost the immune system to recognize and attack tumors.

Learn More

Collaborators

Collaborators
OncoSec continues to establish relationships with industry leaders to further advance our research.

Learn More